Ajanta Pharma Limited
All news and filings related to Ajanta Pharma Limited.
View all news & filings- Medium impact
Ajanta Pharma Releases Sustainability Report for FY 2025-26
Ajanta Pharma has released its FY 2025-26 Sustainability Report, detailing ESG progress. Key achievements include a 47% reduction in Scope 1 emissions, zero workplace fatalities, and 1.5 lakh KL water conservation potential. The company invested ₹252 crore in R&D and reported significant CSR spending. It also achieved Great Place To Work certification.
Read the summary - Low impact
Ajanta Pharma: Trading Window Closed Oct 1, 2026, for Q2 FY27 Results
Ajanta Pharma's trading window will be closed from October 1, 2026. This closure is to facilitate the declaration of financial results for the second quarter and half year ended September 30, 2026. The window will reopen 48 hours after the results announcement.
Read the summary - Low impact
Ajanta Pharma Schedules Analyst/Institutional Investor Meetings in September 2026
Ajanta Pharma Limited will hold investor meetings in September 2026. A one-on-one meeting is scheduled for September 16th as part of the Jefferies India Forum. The company will also attend the PL Capital Mid & Small Cap Conference on September 28th.
Read the summary - Low impact
Ajanta Pharma: Newspaper notice on transfer of shares to IEPF
Ajanta Pharma Limited published a notice regarding the transfer of equity shares to the IEPF for unclaimed dividends over the last seven years. Shareholders must lodge claims by August 1, 2026, to avoid transfer of shares to IEPF on August 11, 2026. This action follows SEBI regulations and the Companies Act.
Read the summary - Low impact
Ajanta Pharma Schedules Analyst/Investor Meetings in August 2026
Ajanta Pharma will hold investor meetings in August 2026. These include the Nuvama India Conference (Aug 11-13) in Singapore & Hong Kong and the Motilal Annual Global Conference (Aug 18) in Mumbai. Discussions will be based on published information.
Read the summary - Low impact
Ajanta Pharma Releases Q1 FY27 Earnings Call Transcript
Ajanta Pharma Limited has published the earnings call transcript for Q1 FY27 (April-June 2026). The transcript, detailing the company's performance, is available on the company's website. The call was held on July 30, 2026.
Read the summary - Low impact
Ajanta Pharma Publishes Q1 FY27 Financial Results
Ajanta Pharma Limited announced its financial results for the quarter ended June 30, 2026. The results were published on July 31, 2026, in Business Standard and Navakal newspapers, in compliance with SEBI regulations.
Read the summary - Low impact
Ajanta Pharma Releases Earnings Call Audio Recording for Q1 FY27
Ajanta Pharma Limited has uploaded the audio recording of its earnings call held on July 30, 2026. The recording is available on the company's website. A written transcript will be provided later.
Read the summary - Low impact
Ajanta Pharma Allots 23,400 Equity Shares Upon Exercise of Options
Ajanta Pharma Limited allotted 23,400 equity shares upon exercise of options. The company's paid-up capital increased to ₹24,99,18,048, comprising 12,49,59,024 equity shares of ₹2 each. Application for listing of these shares will be made shortly.
Read the summary - High impact
Ajanta Pharma Approves ₹32/Share Interim Dividend, Q1 Revenue Up 25%
Ajanta Pharma reported Q1 FY2027 consolidated revenue of ₹1,626 crore (up 25%) and PAT of ₹334 crore (up 31%). The board approved a first interim dividend of ₹32 per share, amounting to ₹400 crore. The record date is August 5, 2026.
Read the summary - Low impact
Ajanta Pharma Sets August 5, 2026, as Record Date for 1st Interim Dividend
Ajanta Pharma Limited has set August 5, 2026, as the record date to determine eligible shareholders for its first interim dividend. This announcement is in compliance with SEBI regulations.
Read the summary - High impact
Ajanta Pharma declares ₹32 interim dividend; Q1 FY27 Consolidated Revenue up 25% to ₹1,626 cr.
Ajanta Pharma reported Q1 FY27 consolidated revenue of ₹1,626 crore, up 25% YoY. PAT increased 31% to ₹334 crore. The board declared an interim dividend of ₹32 per share, totaling ₹400 crore. Key growth drivers included Branded Generics (up 13%) and US Generics (up 57%).
Read the summary - Low impact
Ajanta Pharma revises concall time to 4:15 PM IST on July 30, 2026
Ajanta Pharma Limited will release its Q1 FY2027 unaudited financial results on July 30, 2026. The associated Earnings Conference Call has been rescheduled to 4:15 PM IST on the same day. The company will discuss financial performance and take questions during the call.
Read the summary - Medium impact
Ajanta Pharma to announce Q1 FY27 results on July 30, 2026, followed by concall.
Ajanta Pharma will announce its Q1 FY27 unaudited financial results on July 30, 2026. An earnings conference call is scheduled for the same day at 16:30 IST, where management will discuss performance and take questions.
Read the summary - Low impact
Ajanta Pharma Concludes 47th AGM; All Resolutions Passed
Ajanta Pharma Limited held its 47th AGM on July 16, 2026. All four resolutions, including the adoption of FY25 financial statements and confirmation of interim dividend for FY26, were passed. Mr. Mannalal Bhagwandas Agrawal was reappointed as Director. Remuneration of cost auditors for FY25-27 was also ratified.
Read the summary - Low impact
Ajanta Pharma Holds 47th AGM on July 16, 2026, Approves Financials and Dividend
Ajanta Pharma Limited conducted its 47th Annual General Meeting on July 16, 2026, via video conference. Key resolutions included adopting financial statements for the year ended March 31, 2026, and confirming the interim dividend as final. The meeting also approved the re-appointment of Chairman Mr. Mannalal B. Agrawal.
Read the summary - Low impact
Ajanta Pharma: Certificate for Q1FY27 Dematerialization Compliance
Ajanta Pharma Limited received a compliance certificate for Q1FY27 from its RTA, MUFG Intime India Private Limited. The certificate confirms adherence to SEBI (Depositories and Participants) Regulations, 2018, regarding dematerialisation processes for the quarter ending June 30, 2026.
Read the summary - Medium impact
Ajanta Pharma Paithan Facility Receives VAI Classification from USFDA
Ajanta Pharma's Paithan manufacturing facility has received a Voluntary Action Indicated (VAI) classification from the USFDA following an inspection conducted from April 13-21, 2026. The company has received the Establishment Inspection Report (EIR).
Read the summary - Low impact
Ajanta Pharma: Trading Window Closed for Q1 FY27 Results
Ajanta Pharma Limited will close its trading window from July 1, 2026. The window will reopen 48 hours after the declaration of financial results for the quarter ended June 30, 2026, as per SEBI regulations.
Read the summary - Low impact
Ajanta Pharma Limited Announces 47th AGM E-voting Information
Ajanta Pharma Limited has announced e-voting information for its 47th AGM, scheduled for July 16, 2026. The notice was published on June 19, 2026, in Free Press Journal and Navshakti. Details regarding the AGM and the annual report are available on the company's website and stock exchange portals.
Read the summary - Low impact
Ajanta Pharma Announces 47th AGM on July 16, 2026, Submits FY26 Annual Report
Ajanta Pharma will hold its 47th AGM on July 16, 2026. The company reported FY26 revenue of ₹5,453 crore, a 17% increase. Adjusted EBITDA rose 18% to ₹1,498 crore, and PAT grew 15% to ₹1,056 crore. The annual report for FY25-26 was also submitted.
Read the summary - Low impact
Ajanta Pharma to hold 47th AGM on July 16, 2026 via Video Conference
Ajanta Pharma Limited will hold its 47th Annual General Meeting on July 16, 2026. The meeting will be conducted via Video Conference/Other Audio-Visual Means. This complies with SEBI regulations and MCA circulars.
Read the summary - Low impact
Ajanta Pharma to hold 47th AGM on July 16, 2026, via VC/OAVM
Ajanta Pharma Limited will hold its 47th Annual General Meeting on July 16, 2026, at 11:00 a.m. IST via Video Conferencing. The cut-off date for voting eligibility is July 9, 2026. The Annual Report for FY 2025-26 will be dispatched shortly.
Read the summary - Low impact
Ajanta Pharma to Meet Domestic Institutional Investors on June 17-18
Ajanta Pharma Limited will hold one-on-one meetings with Domestic Institutional Investors (DII's) on June 17th and 18th, 2026, in Mumbai. The discussions will be based on previously published information. The schedule is subject to change.
Read the summary - Low impact
Ajanta Pharma Revises Analyst Meet Schedule for May-June 2026
Ajanta Pharma Limited revised its schedule for investor meetings. The 360 ONE Capital Annual Investor Conference is on May 29, 2026, and the ICICI Securities India Investor Conference is on June 8, 2026. Discussions will be based on published information.
Read the summary - Low impact
Ajanta Pharma Announces Analyst/Institutional Investor Meetings in May and June 2026
Ajanta Pharma has announced analyst/institutional investor meetings. The first meeting is scheduled for 29 May 2026 at the ICICI Securities India Investor Conference. The second meeting will be on 8 June 2026 at the 360 ONE Capital(B&K) Annual Investor Conference. The schedule is subject to change, and discussions will be based on published information.
Read the summary - Low impact
Ajanta Pharma: Transcript of Q4 FY26 Earnings Call Released
Ajanta Pharma Limited released the written transcript of its Q4 FY26 earnings call held on May 5, 2026. The transcript details the company's financial performance and outlook for the quarter ending March 31, 2026. It is available on the company's website.
Read the summary - Low impact
Ajanta Pharma Releases Earnings Call Audio Recording for Q4 FY26
Ajanta Pharma has released the audio recording of its Q4 FY26 earnings call held on May 5th, 2026. A written transcript will be provided shortly. The recording is available on the company's website.
Read the summary - Low impact
Ajanta Pharma Reappoints Internal, Cost, and Tax Auditors for FY27
Ajanta Pharma's Board, in a meeting on May 5, 2026, re-appointed M/s. Aneja Assurance Pvt. Ltd. as Internal Auditors, M/s. RA & Co. as Cost Auditors, and M/s. R S Sanghai & Associates as Tax Auditors for FY 2026-27.
Read the summary - Low impact
Ajanta Pharma Grants 1.45 Lakh ESOPs, Cancels 850 Options
Ajanta Pharma Limited announced the grant of 1,45,000 stock options under its Share Based Incentive Plan 2019. The company also approved the cancellation of 850 stock options, which were returned to the ESOP pool. The exercise period for granted options is three months from vesting.
Read the summary - Medium impact
Ajanta Pharma's Paithan facility receives 5 observations from US FDA inspection
Ajanta Pharma's manufacturing facility in Paithan, Maharashtra, underwent a US FDA inspection from April 13th to April 21st, 2026. The inspection resulted in the issuance of a Form-483 with five observations. The company will respond to the FDA within the stipulated timeline.
Read the summary - Medium impact
Ajanta Pharma Announces Q4 FY26 Results & Earnings Conference Call on May 5
Ajanta Pharma Limited will announce its Q4 FY26 audited financial results on May 5, 2026. An Earnings Conference Call is scheduled for the same day at 16:30 IST to discuss financial performance and answer questions. A transcript will be available on the company website.
Read the summary - Low impact
Ajanta Pharma Promoters Disclose No New Encumbrances for FY26
Ajanta Pharma Limited promoters and promoter group have disclosed no new direct or indirect encumbrances for the financial year ending March 31, 2026. This filing is in compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Read the summary - Low impact
Ajanta Pharma Files Certificate Under SEBI Regulations for Q4FY26
Ajanta Pharma Limited submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The RTA, MUFG Intime India, confirmed processing of dematerialised securities.
Read the summary - Low impact
Ajanta Pharma: Trading Window Closed from April 1, 2026, for FY26 Financial Results
Ajanta Pharma's trading window will be closed from April 1, 2026, until 48 hours after the declaration of financial results for the quarter and year ended March 31, 2026. This is in compliance with SEBI regulations.
Read the summary - Low impact
Ajanta Pharma to attend Investec India Promoter & Founder Conference on March 10
Ajanta Pharma Limited will attend the Investec India Promoter & Founder Conference 2026 on March 10, 2026. The company will participate in group and one-on-one meetings. Discussions will be limited to previously published information.
Read the summary - Medium impact
Ajanta Pharma Denies Rumours of Diversification into QSR Sector
Ajanta Pharma Limited denies rumors of raising ₹2,000 crore for diversification into the QSR sector. The company clarified that a promoter group entity is independently acquiring Restaurant Brands Asia, and Ajanta Pharma is not involved.
Read the summary - Low impact
Ajanta Pharma Releases Transcript of Q3 FY26 Earnings Call Held on Jan 30, 2026
Ajanta Pharma Limited has released the written transcript of its earnings call held on January 30, 2026. The transcript details discussions on the company's Q3 FY26 performance and is available on the company's website.
Read the summary - Low impact
Ajanta Pharma Schedules Investor Meetings in February 2026
Ajanta Pharma Limited will hold investor meetings in February 2026. Meetings are scheduled with Axis Capital on February 10, Nuvama India Conference on February 10, and Kotak Flagship Conference on February 24. Discussions will be based on published information.
Read the summary - Low impact
Ajanta Pharma Publishes Q3 FY26 Financial Results in Newspapers
Ajanta Pharma published its unaudited Q3 FY26 results. For the quarter ended Dec 31, 2025, total income was ₹1,472.67 lakh and profit after tax was ₹18.79 lakh. For the nine months ended Dec 31, 2025, total income was ₹6,391.76 lakh and profit after tax was ₹45.95 lakh. EPS for the quarter was ₹0.21.
Read the summary - Low impact
Ajanta Pharma: Audio Recording of Q3 FY26 Earnings Call Uploaded
Ajanta Pharma Limited has uploaded the audio recording of its Q3 FY26 earnings call held on January 30, 2026. A written transcript will be provided subsequently. The recording is available on the company's website.
Read the summary - Low impact
Ajanta Pharma Approves Vesting of SARs, Cancellation of ESOPs
Ajanta Pharma's Nomination and Remuneration Committee approved the vesting of 4,300 cash-settled SARs on Jan 31, 2026. Settlement will be in cash based on the Feb 2, 2026 closing price, with no equity dilution. 800 ESOPs were also cancelled as grantees ceased employment.
Read the summary - High impact
Ajanta Pharma Q3 FY26 Revenue Up 20% to ₹1,375 Cr, PAT Up 18% to ₹274 Cr
Ajanta Pharma reported Q3 FY26 revenue of ₹1,375 crore, a 20% increase year-on-year. PAT rose 18% to ₹274 crore. For 9M FY26, revenue was ₹4,031 crore (up 16%) and PAT was ₹789 crore (up 14%). Branded Generics in India grew 19%, and US Generics surged 52% in Q3 FY26. An earnings conference call is scheduled for January 30, 2026.
Read the summary - High impact
Ajanta Pharma Q3 FY26: Revenue up 20% to ₹1,375 cr, PAT up 18% to ₹274 cr
Ajanta Pharma reported Q3 FY26 consolidated revenue of ₹1,375 crore, up 20%, and PAT of ₹274 crore, up 18%. For 9M FY26, revenue was ₹4,031 crore (up 16%) and PAT was ₹789 crore (up 14%). US Generics revenue grew 52% to ₹399 crore. The company announced an Earnings Conference Call for January 30, 2026.
Read the summary - Low impact
Ajanta Pharma Denies Stake Acquisition Rumours in Restaurant Brands Asia
Ajanta Pharma Limited denies reports of acquiring a stake in Restaurant Brands Asia. The company clarified that it is not involved in any discussions, negotiations, or proposals related to acquiring a stake in the Burger King operator or any of its franchise entities. The reference in the news article is incorrect.
Read the summary - Low impact
Ajanta Pharma Incorporates Wholly Owned Subsidiary in Ireland
Ajanta Pharma Limited has incorporated a wholly owned subsidiary in Ireland named "Ajanta Pharma Ireland Ltd." The subsidiary will focus on the pharmaceutical products business. This is a new incorporation, and no financial consideration or regulatory approvals are mentioned at this stage.
Read the summary - Medium impact
Ajanta Pharma Schedules Q3 FY26 Results Release and Earnings Call for Jan 30, 2026
Ajanta Pharma will announce its Q3 FY26 unaudited financial results on January 30, 2026. An Earnings Conference Call is scheduled for the same day at 16:30 hrs IST to discuss performance and answer questions.
Read the summary - Low impact
Ajanta Pharma Files SEBI Compliance Certificate for Q3 FY26
Ajanta Pharma Limited submitted a SEBI compliance certificate for the quarter ended December 31, 2025. The certificate confirms the processing of dematerialised securities by the Registrar and Share Transfer Agent, MUFG Intime India Private Limited.
Read the summary - Low impact
Ajanta Pharma: Trading Window Closed Jan 1, 2026, for Q3 FY26 Results
Ajanta Pharma's trading window will be closed from January 1, 2026, until 48 hours after the declaration of its Q3 FY26 financial results, which are for the nine months ending December 31, 2025.
Read the summary - Medium impact
Ajanta Pharma inks in-licensing deal with Biocon for Semaglutide marketing
Ajanta Pharma has entered an in-licensing agreement with Biocon for Semaglutide marketing across 26 countries in Africa, the Middle East, and Central Asia. The product patent expires in March 2026, with expected regulatory approvals in late 2026 or early 2027. Ajanta Pharma reported FY25 revenue of ₹4,648 crore.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio